DIAGNOS Inc. (DGNOF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DIAGNOS Inc. (DGNOF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 36/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026DIAGNOS Inc. (DGNOF) Resumen de Asistencia Médica y Tuberías
DIAGNOS Inc. provides software-based healthcare solutions, focusing on early detection of diabetic retinopathy through its CARA platform. Operating across several countries, the company leverages AI and data analysis to enhance diagnostic capabilities for eye care professionals, positioning itself in the evolving landscape of healthcare information services.
Tesis de Inversión
DIAGNOS Inc. presents a speculative investment opportunity within the healthcare information services sector. The company's CARA platform addresses a critical need for early detection of diabetic retinopathy, a growing concern globally. However, with a negative P/E ratio of -7.48 and a significantly negative profit margin of -6907.3%, the company's financial performance raises concerns about its profitability and sustainability. The potential for growth lies in expanding the adoption of the CARA platform and leveraging its AI and data analysis capabilities. Investors should closely monitor the company's ability to improve its financial metrics and secure additional contracts in its target markets. The low Beta of -0.17 suggests the stock is less volatile than the market, but this may also reflect limited trading activity and investor interest.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.02 billion indicates a micro-cap company with potential for high growth but also significant risk.
- Negative P/E ratio of -7.48 reflects current unprofitability, requiring careful monitoring of future earnings potential.
- Gross margin of -2090.9% signals substantial challenges in cost management and pricing strategies.
- The company's focus on Computer Assisted Retina Analysis (CARA) positions it in a niche market with potential for expansion.
- Operations across multiple countries, including Canada, the United States, and several Latin American nations, provide geographic diversification.
Competidores y Pares
Fortalezas
- Proprietary CARA platform for diabetic retinopathy detection.
- Expertise in AI and data analysis.
- Established presence in multiple countries.
- Focus on a specific niche within healthcare.
Debilidades
- Negative P/E ratio and profit margin.
- Limited financial resources.
- Reliance on a single product (CARA).
- Small market capitalization.
Catalizadores
- Upcoming: Potential new partnerships with healthcare providers to expand CARA platform adoption.
- Ongoing: Increasing prevalence of diabetes driving demand for diabetic retinopathy detection solutions.
- Ongoing: Development of new AI-powered diagnostic tools to diversify revenue streams.
Riesgos
- Potential: Competition from larger healthcare companies with more resources.
- Potential: Regulatory changes in healthcare affecting the adoption of AI-powered diagnostic tools.
- Ongoing: Negative P/E ratio and profit margin indicating financial instability.
- Potential: Limited liquidity and wider bid-ask spreads on the OTC market.
Oportunidades de crecimiento
- Expansion of CARA Platform Adoption: DIAGNOS has the opportunity to increase the adoption of its CARA platform among healthcare providers globally. The rising prevalence of diabetes and the need for early detection of diabetic retinopathy create a significant market. By targeting regions with limited access to specialized eye care, DIAGNOS can expand its market share and generate recurring revenue through software subscriptions and service fees. Market research indicates the global diabetic retinopathy market is projected to reach $4.6 billion by 2027, offering substantial growth potential.
- Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with hospitals, clinics, and eye care centers can accelerate the adoption of DIAGNOS's CARA platform. These partnerships can provide access to a broader patient base and facilitate the integration of CARA into existing clinical workflows. By collaborating with key opinion leaders and participating in industry conferences, DIAGNOS can enhance its visibility and credibility within the healthcare community. The timeline for establishing these partnerships is estimated at 1-2 years, with potential revenue impact within 2-3 years.
- Development of New AI-Powered Diagnostic Tools: DIAGNOS can leverage its expertise in AI and data analysis to develop new diagnostic tools for other medical conditions. By expanding its product portfolio, the company can diversify its revenue streams and reduce its reliance on a single product. Potential areas for expansion include cardiovascular disease, neurological disorders, and cancer screening. The development of new AI-powered diagnostic tools requires significant investment in research and development, with a timeline of 2-3 years for product launch.
- Geographic Expansion into Emerging Markets: DIAGNOS can expand its geographic presence into emerging markets with high rates of diabetes and limited access to specialized eye care. These markets offer significant growth potential due to the unmet need for affordable and accessible diagnostic solutions. By adapting its CARA platform to local languages and regulatory requirements, DIAGNOS can penetrate these markets and establish a strong foothold. The timeline for geographic expansion is estimated at 1-2 years, with potential revenue impact within 2-3 years.
- Leveraging Telemedicine for Remote Diagnostics: Integrating the CARA platform with telemedicine services can enable remote diagnostics and expand access to eye care in underserved areas. By partnering with telemedicine providers, DIAGNOS can offer its diagnostic services to patients who may not have access to traditional healthcare facilities. This approach can also reduce the cost of healthcare delivery and improve patient outcomes. The integration of CARA with telemedicine platforms requires collaboration with technology providers and regulatory approvals, with a timeline of 1-2 years for implementation.
Oportunidades
- Expansion of CARA platform adoption.
- Strategic partnerships with healthcare providers.
- Development of new AI-powered diagnostic tools.
- Geographic expansion into emerging markets.
Amenazas
- Competition from larger healthcare companies.
- Regulatory changes in healthcare.
- Technological advancements that could render CARA obsolete.
- Economic downturn affecting healthcare spending.
Ventajas competitivas
- Proprietary Computer Assisted Retina Analysis (CARA) software.
- Expertise in AI and data analysis for healthcare.
- Established presence in multiple countries.
- Partnerships with healthcare providers.
Acerca de DGNOF
Founded in 1998 and headquartered in Brossard, Canada, DIAGNOS Inc. has established itself as a provider of software-based services within the healthcare sector. The company's core offering is the Computer Assisted Retina Analysis (CARA) platform, a web-based tool designed to aid healthcare professionals in the early detection of diabetic retinopathy. This technology allows eye care specialists to visualize retinal landmarks and identify pathological changes indicative of the disease. DIAGNOS operates across Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica, reflecting a global reach in its service delivery. Beyond its diagnostic software, DIAGNOS also provides consulting services in data analysis and artificial intelligence, leveraging its expertise to offer broader solutions within the healthcare industry. The company's focus on innovative technology and international expansion underscores its commitment to improving healthcare outcomes through advanced diagnostic tools and services.
Qué hacen
- Provides Computer Assisted Retina Analysis (CARA) software.
- CARA assists in the early detection of diabetic retinopathy.
- Offers a web-based platform for healthcare professionals.
- Visualizes retinal landmarks and pathological changes.
- Provides consulting services in data analysis.
- Offers expertise in artificial intelligence for healthcare applications.
Modelo de Negocio
- Software-as-a-Service (SaaS) model for the CARA platform.
- Revenue from subscriptions and service fees.
- Consulting services in data analysis and AI.
- Partnerships with healthcare providers and telemedicine companies.
Contexto de la Industria
DIAGNOS Inc. operates within the healthcare information services sector, which is experiencing growth driven by technological advancements and increasing demand for efficient diagnostic tools. The market for AI-powered diagnostic solutions is expanding, with companies like DIAGNOS leveraging these technologies to improve healthcare outcomes. The competitive landscape includes established players in medical imaging and diagnostics, as well as emerging companies focused on AI-driven healthcare solutions. DIAGNOS's focus on diabetic retinopathy detection positions it within a specific niche of the broader healthcare IT market.
Clientes Clave
- Eye care specialists
- Hospitals and clinics
- Healthcare providers
- Telemedicine companies
Finanzas
Gráfico e información
Precio de la acción de DIAGNOS Inc. (DGNOF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para DGNOF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para DGNOF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para DGNOF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de DGNOF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Andre Larente
CEO
Andre Larente serves as the CEO of DIAGNOS Inc. His background includes experience in the technology and healthcare sectors. He has been involved in the development and commercialization of innovative healthcare solutions. Larente's expertise lies in strategic planning, business development, and market expansion. He is responsible for driving the company's growth and executing its strategic vision. His leadership aims to position DIAGNOS as a leading provider of AI-powered diagnostic solutions.
Historial: Under Andre Larente's leadership, DIAGNOS Inc. has focused on expanding the adoption of its CARA platform and developing new AI-powered diagnostic tools. He has overseen the company's efforts to secure partnerships with healthcare providers and expand its geographic presence. Key milestones include the commercialization of the CARA platform in multiple countries and the development of new AI algorithms for disease detection. His tenure has been marked by a focus on innovation and strategic growth.
Información del mercado OTC de DGNOF
The OTC Other tier represents the lowest tier of the OTC market, indicating that DIAGNOS Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial disclosures. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ, as they may lack the same level of regulatory oversight and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited liquidity and wider bid-ask spreads.
- Lack of regulatory oversight and transparency.
- Potential for price manipulation and fraud.
- Higher risk of financial distress or bankruptcy.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any legal or regulatory issues.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Established presence in multiple countries.
- Proprietary CARA platform for diabetic retinopathy detection.
- Partnerships with healthcare providers.
- Focus on AI and data analysis for healthcare applications.
DGNOF Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar DGNOF?
DIAGNOS Inc. (DGNOF) actualmente tiene una puntuación IA de 36/100, indicando puntuación baja. Fortaleza clave: Proprietary CARA platform for diabetic retinopathy detection.. Riesgo principal a monitorear: Potential: Competition from larger healthcare companies with more resources.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de DGNOF?
DGNOF actualmente puntúa 36/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de DGNOF?
Los precios de DGNOF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre DGNOF?
La cobertura de analistas para DGNOF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en DGNOF?
Las categorías de riesgo para DGNOF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from larger healthcare companies with more resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de DGNOF?
La relación P/E para DGNOF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está DGNOF sobrevalorada o infravalorada?
Determinar si DIAGNOS Inc. (DGNOF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de DGNOF?
DIAGNOS Inc. (DGNOF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited analyst coverage for DGNOF.
- Financial data based on available information as of 2026-03-16.
- OTC market investments carry higher risk.